Abstracts tagged "osteoblasts and osteoclastogenesis"

Abstract Number: 1098 • 2016 ACR/ARHP Annual Meeting
ZCCHC6/TUT7 Negatively Regulates Osterix Activity and Influences Osteoblast-Mediated Regulation of Osteoclastogenesis
Gregory Sondag¹, Mohammad Khan¹, Mohammad Ansari², Nazar Hussein^1,3, Sara Haynie¹, Fayez Safadi¹ and Tariq M. Haqqi¹, ¹Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH, ²Anatomy & Neurobiology, Northeast Ohio Medical University, Roostown, OH, ³School of Biomedical Sciences, Kent State University, Kent, OH
Background/Purpose: Mechanisms associated with intrinsic mRNA regulation are important players in development and disease processes. The terminal uridylyl transferases (TUT) are a family of enzymes…
Abstract Number: 1965 • 2012 ACR/ARHP Annual Meeting
Adenosine Regulates Bone Metabolism Via A₁, A_2A and A_2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma
Wenjie He¹, Amitabha Mazumder² and Bruce N. Cronstein³, ¹Dept of Med, Div of Rheum, NYU, New York, NY, ²NYU Cancer Center, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Multiple myeloma is a haematologic malignancy that is characterized by osteolytic bone lesions, wherein coupled bone remodeling is disrupted with increased osteoclast activation and…
Abstract Number: 45 • 2012 ACR/ARHP Annual Meeting
The Effects of Apremilast On Osteoclasts, Osteoblasts, and Osteocytes
Mary Adams and Peter Schafer, Department of Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Apremilast (APR), a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro- and anti-inflammatory mediator production in both immune and non-immune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].